natgillin/translations-raw huggingface dataset:
• the CHMP considered that the amount of active substance in the finished product is determined and consistently based on the potency expressed in IU, and that the dose and strength of vancomycin containing products should continue to be expressed in milligrams, 
• odbor CHMP je menil, da mora količina zdravilne učinkovine v končnem zdravilu dosledno temeljiti na potenci, izraženi v mednarodnih enotah (i.e.), in da je treba odmerek in jakost zdravil, ki vsebujejo vankomicin, še naprej izražati v miligramih.
Vancomycin is also administered by the oral route for the treatment of Clostridium difficile-infection (CDI). 
Vankomicin se daje tudi peroralno za zdravljenje okužbe s Clostridium difficile (Clostridium difficile, CDI).
As a consequence, the CHMP is of the view that the benefit-risk for vancomycin containing products in the indication “Decontamination of the gastrointestinal tract in immune-compromised patients when combined with an aminoglycoside” is not established and therefore this indication is not recommended. 
Posledično odbor CHMP meni, da razmerje med koristmi in tveganji za zdravila, ki vsebujejo vankomicin, pri indikaciji „dekontaminacija prebavil pri bolnikih z oslabljenim imunskim sistemom v kombinaciji z aminoglikozidom“ ni pojasnjeno in zato indikacija ni priporočljiva.
The CHMP noted the guidelines on the management of Peritoneal Dialysis-related peritonitis in adults from the International Society for Peritoneal Dialysis (ISPD) (Li PK et al., 20167), the ISPD recommendations for pediatric patients (Warady BA et al., 20128). 
Odbor CHMP je upošteval smernice za obravnavo peritonitisa, povezanega s peritonealno dializo, pri odraslih, ki jih je pripravilo Mednarodno združenje za peritonealno dializo (ISPD) (Li PK et al., 20167) in priporočila ISPD za pediatrične bolnike (Warady BA et al., 20128).
The CHMP also reviewed the existing data on adverse reactions observed with the use of vancomycin and which confirm that the use of vancomycin for parenteral use is associated with nephrotoxicity and ototoxicity, infusion related adverse reactions like vein and tissue toxicity as well as hypersensitivity reactions. 
Odbor je pregledal tudi obstoječe podatke o opaženih neželenih učinkih zaradi uporabe vankomicina, ki potrjujejo, da je parenteralna uporaba vankomicina povezana z nefrotoksičnostjo in ototoksičnostjo, neželenimi učinki, povezanimi z infundiranjem, kot so toksični učinki na vene in tkiva ter preobčutljivostne reakcije.
5 IDSA: http://www.idsociety.org/Guidelines/Patient_Care/IDSA_Practice_Guidelines/Infections_by_Organ_System/Central_Nervous_System_(CNS)/B acterial_Meningitis/ 
5 Ameriško združenje za infekcijske bolezni (IDSA): http://www.idsociety.org/Guidelines/Patient_Care/IDSA_Practice_Guidelines/Infections_by_Organ_System/Central_Nervous_System_(CNS)/B acterial_Meningitis/.
Intravenous vancomycin is mainly used for the treatment of serious infections caused by microorganisms with mechanisms of resistance to beta-lactam antibiotics, in particular methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CoNS) and enterococci, the latter being often tolerant to β-lactam antibiotics. 
Vankomicin se intravensko uporablja predvsem za zdravljenje resnih okužb z mikroorganizmi, ki imajo mehanizme odpornosti proti betalaktamskim antibiotikom, zlasti okužb s proti meticilinu odporno bakterijo Staphylococcus aureus (MRSA) in koagulazno negativnim stafilokokom (KNS), ter enterokoki, pri katerih se pogosto pojavlja toleranca na betalaktamske antibiotike.
Grounds for the variation to the terms of the marketing authorisation, as applicable 
Podlaga za ustrezno spremembo pogojev dovoljenja za promet z zdravilom
In its assessment, the CHMP reviewed all available data, including submissions by the marketing authorisation holders during the procedure and consulted the Paediatric Committee (PDCO), the CHMP relevant working parties/groups: Infectious Disease working party (IDWP), the Pharmacokinetics working party (PKWP), the Quality Working Party (QWP), the Modelling and Simulation Working Group (MSWG)) and external experts (the European Committee on Antimicrobial Susceptibility Testing (EUCAST)). 
Odbor CHMP je med postopkom pregledal vse razpoložljive podatke, vključno z vlogami imetnikov dovoljenj za promet z zdravilom, in se posvetoval z Odborom za pediatrijo (PDCO), ustreznimi delovnimi skupinami/skupinami odbora CHMP: delovno skupino za nalezljive bolezni (IDWP), delovno skupino za farmakokinetiko (PKWP), delovno skupino za kakovost (QWP), delovno skupino za modeliranje in simulacije (MSWG) ter zunanjimi strokovnjaki (Evropskim odborom za testiranje protimikrobne občutljivosti (EUCAST)).
In conclusion, the CHMP is of the opinion that the benefit-risk balance of the vancomycin-containing products included in the scope of this procedure remains positive under normal conditions of use, taking into account the agreed changes to the product information as set out in Annex III to the opinion. 
Na koncu je Odbor menil, da razmerje med koristmi in tveganji za zdravila, ki vsebujejo vankomicin in so bila zajeta v tem postopku, ostaja pozitivno pri normalnih pogojih uporabe, ob upoštevanju dogovorjenih sprememb informacij o zdravilu, kot je določeno v Prilogi III k mnenju.
The following indications of vancomycin (oral route) for “treatment of staphylococcal enterocolitis” and “Decontamination of the gastrointestinal (GI) tract in immune-compromised patients when combined with an aminoglycoside” were not supported by the CHMP: 
Indikacije za vankomicin (peroralno) za „zdravljenje stafilokoknega enterokolitisa“ in „dekontaminacijo prebavil pri bolnikih z oslabljenim imunskim sistemom v kombinaciji z aminoglikozidom" odbor CHMP ni podprl:
8 ISPD recommendations for paediatric patients (Warady BA et al., 2012) - https://ispd.org/media/pdf/Consensus__Change_20_.pdf 9https://www.escmid.org/fileadmin/src/media/PDFs/4ESCMID_Library/2Medical_Guidelines/ESCMID_Guidelines/fulltext_treatment_guidance_ Clostridium_difficile_infection.pdf 
8 Priporočila ISPD za pediatrične bolnike (Warady BA et al., 2012) - https://ispd.org/media/pdf/Consensus__Change_20_.pdf.
CHMP was of the opinion that, given the fact that the use of milligram to prescribe this product was established in EU clinical practice, it is essential that the convention of labelling vancomycin products by mass, i.e. milligrams, is retained. 
Glede na dejstvo, da se je v klinični praksi EU uveljavila uporaba miligramov za predpisovanje zdravila, je Odbor menil, da je bistveno, da se ohrani dogovorjeno označevanje zdravil, ki vsebujejo vankomicin, z maso, tj. miligrami.
As a consequence, the CHMP could not recommend any concrete dosing recommendations for continuous infusion in the SmPC of vancomycin for IV use. 
Posledično odbor CHMP ni mogel pripraviti konkretnih priporočil za odmerjanje v obliki neprekinjenega infundiranja za povzetek glavnih značilnosti za vankomicin pri intravenozni uporabi.
• the CHMP carried out a benefit-risk evaluation of vancomycin containing products under Article 31 of Directive 2001/83/EC, reviewing all available data, including responses submitted by the marketing authorisation holders during the procedure and recommendations from the Paediatric Committee (PDCO), the CHMP relevant working parties/groups: Infectious Disease working party (IDWP), the Pharmacokinetics working party (PKWP), the Quality Working Party (QWP), the Modelling and Simulation Working Group (MSWG)) and external experts (the European Committee on Antimicrobial Susceptibility Testing (EUCAST), 
• odbor CHMP je izvedel oceno razmerja med koristmi in tveganji zdravil, ki vsebujejo vankomicin, v skladu s členom 31 Direktive 2001/83/ES, in pregledal vse razpoložljive podatke, vključno z odzivi, ki so jih med postopkom predložili imetniki dovoljenj za promet z zdravilom, in priporočili Odbora za pediatrijo (PDCO) ter ustreznih delovnih skupin odbora CHMP: delovne skupine za nalezljive bolezni (IDWP), delovne skupine za farmakokinetiko (PKWP), delovne skupine za kakovost (QWP), delovne skupine za modeliranje in simulacije (MSWG) ter zunanjih strokovnjakov (Evropskega odbora za testiranje protimikrobne občutljivosti (EUCAST);
Overall, the CHMP considered that, out of the discussed methods, the Bayesian interpolation seemed to be an appropriate alternative; it allows predicting many individual pharmacokinetic parameters for extrapolation, minimizes the number of measurements on a single patient and seems to develop optimal strategies for therapeutic intervention. 
Ta omogoča napovedovanje številnih posameznih farmakokinetičnih parametrov za ekstrapolacijo, zmanjšuje število meritev pri enem bolniku in, kot kaže, omogoča razvoj optimalnih strategij za terapevtsko intervencijo.
6 Joint guideline: https://www.britishinfection.org/files/5614/5674/2938/McGill_meningitis_guidelines_Final_published_proof.pdf 7 PD-related peritonitis https://ispd.org/ispd-guidelines/ guidelines on the management of PD-related peritonitis in adults from the International Society for Peritoneal Dialysis (ISPD) (Li PK et al., 2016 http://www.pdiconnect.com/content/36/5/481.full 
7 Peritonitis, povezan s peritonealno dializo https://ispd.org/ispd-guidelines/ Smernice za obravnavo peritonitisa, povezanega s peritonealno dializo pri odraslih iz Mednarodnega združenja za peritonealno dializo (ISPD) (Li PK et al., 2016 http://www.pdiconnect.com/content/36/5/481.full.
For both infants, children aged from one month to 18 years old, the CHMP agreed that, as for adults, the vancomycin dose should be individually adapted according to weight, age and the underlying type and severity of infection and clinical response; the initial vancomycin doses should be calculated based on the body weight. 
Odbor je za dojenčke in otroke v starosti od enega meseca do 18 let menil, da je treba odmerek vankomicina individualno prilagoditi glede na telesno maso, starost, vrsto in resnost osnovne okužbe ter klinični odziv, kot velja za odrasle bolnike.
1 ESCMID guidelines: https://www.escmid.org/escmid_publications/medical_guidelines/escmid_guidelines/ 2 ESCMID guideline https://www.escmid.org/fileadmin/src/media/PDFs/4ESCMID_Library/2Medical_Guidelines/ESCMID_Guidelines/Eu_Rec_Antimicrobal.pdf 3 IDSA guideline http://www.idsociety.org/Guidelines/Patient_Care/IDSA_Practice_Guidelines/Antimicrobial_Agent_Use/Vancomycin/Vancomycin/ 4 Bacterial meningitis:ESCMID guideline for bacterial meningitis: http://www.clinicalmicrobiologyandinfection.com/article/S1198743X(16)00020-3/abstract 
4 Bakterijski meningitis: Smernice ESCMID za bakterijski meningitis: http://www.clinicalmicrobiologyandinfection.com/article/S1198743X(16)00020-3/abstract.
• the CHMP considered that vancomycin represent a crucial therapeutic option in the context of the treatment of serious infections (complicated skin and soft tissue infections, bone and joint infections, community acquired pneumonia, hospital acquired pneumonia including ventilatorassociated pneumonia, infective endocarditis, acute bacterial meningitis, bacteraemia that occurs in association with, or is suspected to be associated with, any of the above, perioperative antibacterial prophylaxis, peritoneal dialysis-associated peritonitis and treatment of Clostridium difficile infection) caused by Gram-positive pathogens, particularly those caused by MRSA, 
• Odbor CHMP je menil, da vankomicin predstavlja ključno terapevtsko možnost pri zdravljenju hudih okužb (zapletenih okužb kože in mehkih tkiv; okužb kosti in sklepov; zunajbolnišnične pljučnice; bolnišnično pridobljene pljučnice, vključno z ventilatorsko pljučnico; infektivnega endokarditisa, akutnega bakterijskega meningitisa; bakteriemije, ki se pojavi v povezavi s katerim koli od zgoraj navedenih stanj ali v primeru suma takšne povezave; pri perioperativni antibakterijski profilaksi, pri zdravljenju peritonitisa, povezanega s peritonealno dializo in zdravljenju okužbe s Clostridium difficile z grampozitivnimi povzročitelji, zlasti MRSA;
• Treatment of Clostridium difficile infection (CDI), for vancomycin given by oral route of administration. 
• Zdravljenje okužb s Clostridium difficile z vankomicinom, uporabljenim peroralno.
• Treatment of: complicated skin and soft tissue infections, bone and joint infections, community acquired pneumonia, hospital acquired pneumonia including ventilator-associated pneumonia, infective endocarditis, bacteraemia that occurs in association with, or is suspected to be associated with any of the above (particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA)), perioperative antibacterial prophylaxis. 
• Zdravljenje: zapletenih okužb kože in mehkih tkiv; okužb kosti in sklepov; zunajbolnišnične pljučnice; bolnišnično pridobljene pljučnice, vključno z ventilatorsko pljučnico; infektivnega endokarditisa; bakteriemije, ki se pojavi v povezavi s katerim koli od zgoraj navedenih stanj (zlasti če je povzročitelj proti meticilinu odporna bakterija Staphylococcus aureus (MRSA)) oziroma obstaja sum takšne povezave; perioperativna antibakterijska profilaksa.
It is currently made clear that TDM frequency needs to be individualised based on the clinical situation and response to treatment; specific recommendations are made for hemodynamically stable and unstable patients, patients with normal renal function and patients on intermittent haemodialysis. 
Priporočila so specifična za hemodinamsko stabilne in nestabilne bolnike, bolnike z normalnim delovanjem ledvic in bolnike na intermitentni hemodializi.
The guidance provides treatment recommendations for initial and recurrent CDI. 
Smernice vsebujejo priporočila za začetno zdravljenje in zdravljenje ponavljajočih se okužb s Clostridium difficile.
will enter into force, the limits of the impurities in the drug substance and final drug products will need to be revised accordingly, where applicable. 
Ko začne v Evropski farmakopeji veljati monografija o vankomicinu, bo treba po potrebi ustrezno popraviti mejne vrednosti nečistoč v zdravilni učinkovini in končnih zdravilih.
Regarding the administration of vancomycin as a continuous infusion in paediatric patients, PDCO confirmed that it is being used in some countries for neonates (and children) with severe infections such as patients with central nervous system infections and/or associated bacteremia. 
Odbor PDCO je potrdil, da se v nekaterih državah pri novorojenčkih (in otrocih) s hudimi okužbami (kot so okužbe centralnega živčnega sistema in/ali povezano bakteriemijo) uporablja dajanje vankomicina v obliki neprekinjenega infundiranja.
However, the CHMP noted that the 2 g/day dose often results in Ctrough values below the target of 10 to 20 mg/l; therefore in order to achieve the optimal target concentration, the CHMP agreed that the vancomycin dose should be individually adapted according to weight, age and the underlying type and severity of infection and clinical response; the initial vancomycin doses should be calculated based on the body weight. 
Odbor je menil, da je treba za doseganje optimalne ciljne koncentracije odmerek vankomicina individualno prilagoditi glede na telesno maso, starost, vrsto in resnost osnovne okužbe ter klinični odziv.
Food enhances the absorption. 
Hrana poveča absorpcijo.
Do not eat, drink or smoke while handling the product. 
Ne jejte, pijte ali kadite, ko delate z zdravilom.
Renal clearance is the minor route of elimination. 
Renalni očistek je manj pomembni način eliminacije.
If the tablet is not taken up voluntarily by the dog it can also be given with food or directly into the mouth. 
Če pes ne vzame tablete prostovoljno, jo lahko daste tudi s hrano ali direktno v gobec.
Individual variation in Cmax and t1/2 was observed. 
Opazovali so posamezno variacijo Cmax in t1/2.
Interaction with other medicinal products and other forms of interaction: None known. 
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij: Niso znane.
The chewable tablets should not be broken or divided. 
Žvečljivih tablet ne smete drobiti ali deliti.
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 
VSEBINA PO TEŽI, VOLUMNU ALI ŠTEVILU ODMERKOV
In some cases, soap and water is not sufficient to remove the product spilled on the fingers, therefore gloves must be used. 
V nekaterih primerih milo in voda ne zadoščata za odstranitev zdravila, ki se je razlilo na prstih, zato je treba uporabiti rokavice.
Use with caution in dogs with pre-existing epilepsy. 
Uporabljajte previdno pri psih z že obstoječo epilepsijo.
Use only accordingly to the benefit/risk assessment by the responsible veterinarian. 
Zdravilo uporabite le v skladu z oceno korist/tveganje odgovornega veterinarja .
Bravecto is a chewable tablet and is well accepted by most dogs. 
Bravecto je žvečljiva tablet in jo večina psov dobro sprejme.
1210 Vienna 
1210 Dunaj
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/). 
Podrobne informacije o tem zdravilu so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency) (http://www.ema.europa.eu/.)
The major route of elimination is the excretion of unchanged fluralaner in faeces (~90% of the dose). 
Pomembnejši način eliminacije je izločanje nespremenjenega fluralanerja v fecesu (~90% odmerka).
Intervet UK Limited Walton Manor, Walton, Milton Keynes, Buckinghamshire, MK7 7AJ UNITED KINGDOM 
Intervet UK Limited Walton Manor, Walton, Milton Keynes, Buckinghamshire, MK7 7AJ Združeno kraljestvo
Convulsions and lethargy has been reported very rarely in spontaneous reports. 
O konvulzijah in letargiji so poročali zelo redko v spontanih poročilih.
People with a sensitive skin or known allergy in general e.g. to other veterinary medicinal products of this type should handle the veterinary medicinal product as well as treated animals with caution. 
Ljudje z občutljivo kožo ali znano alergijo na splošno, npr. na druga zdravila za uporabo v veterinarski medicini tega tipa morajo z zdravili za uporabo v veterinarski medicini in z zdravljenimi živalmi ravnati previdno.
Incompatibilities: None known. 
Inkompatibilnosti: Niso znane.
No treatment-related clinical signs were observed. 
Z zdravljenjem povezanih kliničnih znakov niso opazili.
Major incompatibilities: None known. 
Glavne inkompatibilnosti: Niso znane.
If you notice any side effects, even those not already listed in this package leaflet or you think the medicine has not worked, please inform your veterinary surgeon. 
Če opazite kakršne koli resne stranske učinke, tudi tiste, ki niso navedeni v tem navodilu za uporabo ali mislite, da zdravilo ni delovalo, obvestite svojega veterinarja.
Light to dark brown tablet with a smooth or slightly rough surface and circular shape. 
Svetla do temno rjava tableta z gladko ali rahlo grobo površino okrogle oblike.
Do not wash or allow the dog to become immersed in water or swim in water courses within 3 days after treatment. 
Ne umivajte psa oz. ne dovolite psu, da se kopa ali plava v vodi 3 dni po zdravljenju.
Do not allow recently treated animals to groom each other. 
Ne dovolite ravnokar zdravljenim mačkam da negujejo ena drugo.
The cap will stay on the pipette; it is not possible to remove it. 
Zaporka bo ostala na kapalki; ni je mogoče odstraniti.
Fluralaner is systemically distributed and reaches the highest concentrations in fat, followed by liver, kidney and muscle. 
Fluralaner se sistemsko porazdeli in doseže najvišje koncentracije v maščobi, nato sledijo jetra, ledvice in mišice.
This product is for topical use and should not be administered orally. 
To zdravilo je za lokalno uporabo in se ne sme dajati peroralno.
In case of spillage onto, for example table or floor surfaces, remove excess product using paper tissue and clean the area with detergent. 
V primeru razlitja, na primer po mizi ali po tleh, poberite odvečno zdravilo s papirnati brisačo in očistite površino z detergentom.
Intervet Productions Rue de Lyons 27460 Igoville FRANCE 
Kožni nanos, raztopina: Intervet Productions Rue de Lyons 27460 Igoville Francija
Convulsions and lethargy has been reported very rarely in spontaneous (pharmacovigilance) reports. 
O krčih in letargiji so poročali zelo redko v spontanih (farmakovigilančnih) poročilih.
Read package leaflet for full user safety information. 
Za popolne varnostne informacije preberite navodilo za uporabo.
Do not use directly on skin lesions. 
Ne nanašajte neposredno na poškodovano kožo.
If skin contact does occur, wash the affected area immediately with soap and water. 
Če se pride do stika s kožo, prizadeto območje takoj sperite z milom in vodo.
Wear gloves when handling and administering this product. 
Pri rokovanju in nanašanju zdravila uporabljajte rokavice.
Following oral administration, fluralaner is readily absorbed reaching maximum plasma concentrations within 1 day. 
Po peroralnem dajanju se fluralaner zlahka absorbira in doseže maksimalno koncentracijo v plazmi v 1 dnevu.
The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD). 
To zdravilo se lahko uporablja kot del strategije zdravljenje dermatitisa zaradi alergije na bolhe (FAD).
A plateau is seen in plasma between 7 and 63 days post administration, after which concentrations decline slowly. 
Visok nivo je viden v krvni plazmi med 7. in 63. dnevom po dajanju, nakar koncentracija počasi pada.
In molecular on-target studies on insect GABA receptors of flea and fly, fluralaner is not affected by dieldrin resistance. 
V molekularnih ciljanih študijah na GABA receptorjih bolhe in muhe fluralanerja ne prizadene odpornost na dieldrin.
In in vitro bio-assays, fluralaner is not affected by proven field resistances against amidines (tick), organophosphates (tick, mite), cyclodienes (tick, flea, fly), macrocyclic lactones (sea lice), phenylpyrazoles (tick, flea), benzophenyl ureas (tick), pyrethroids (tick, mite) and carbamates (mite). 
V in vitro biotestih na fluralaner ne vpliva dokazana odpornost na amidine (klop), organofosfate (klop, pršica), ciklodiene (klop, bolha, muha), makrociklične laktone (morske uši), fenilpirazole (klop, bolha), benzofenil uree (klop), piretroide (klop, pršica) in karbamate (pršica).
Sodium lauryl sulfate Disodium embonate monohydrate Magnesium stearate Aspartame 
Natrijev lavrilsulfat Dinatrijev embonat monohidrat Magnezijev stearat Aspartam
and Rhipicephalus sanguineus) and fleas (Ctenocephalides spp.) 
Rhipicephalus sanguineus) in bolham (Ctenocephalides spp.)
Intervet GesmbH Siemensstrasse 107 1210 Vienna AUSTRIA 
Žvečljiva tableta: Intervet GesmbH Siemensstrasse 107 1210 Dunaj Avstrija
The dog should be observed during administration to confirm that the tablet is swallowed. 
Psa je treba opazovati, da vidite, da je tableto pogoltnil.
Step 3: Squeeze the pipette gently and apply the entire contents directly to the dog's skin in one (when volume is small) or several spots along the dog's dorsal line from the shoulder to the base of the tail. 
Tretji korak: Rahlo stiskajte merilno kapalko in nanesite njeno celotno vsebino neposredno na kožo na eno (če je volumen majhen) ali več mestih vzdolž hrbtenice od ramen do korena repa.
on the cat. 
pri mačkah.
It is efficacious against ticks (Ixodes spp.) 
Učinkovit je proti klopom (Ixodes spp.)
It is efficacious against ticks (Ixodes spp., Dermacentor spp. 
Učinkovit je proti klopom (Ixodes spp., Dermacentor spp.
Soya-bean oil 
Sojino olje
Manufacturer responsible for batch release: Intervet GesmbH 
Proizvajalec, odgovoren za sproščanje serij: Intervet GesmbH
The sachets should only be opened immediateley prior to use. 
Vrečke odprite le neposredno pred uporabo.
Date of first authorisation: 11/02/2014 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 11/02/2014
Step 3: Squeeze the pipette gently and apply the entire contents directly to the cat's skin. 
Tretji korak: Narahlo stiskajte merilno kapalko in nanesite njeno celotno vsebino neposredno na kožo.
Parasites need to start feeding on the host to become exposed to fluralaner; therefore the risk of the transmission of parasite borne diseases cannot be excluded. 
Paraziti se morajo začeti hraniti na gostitelju, da so izpostavljeni fluralanerju, zato tveganja prenašanja bolezni, ki jih prenašajo paraziti, ni mogoče izključiti.